Dr. Fox was appointed to the board of directors of GenMark Diagnostics, Inc. in September 2010 and as Chairman in 2014. Dr. Fox has extensive experience in global technology and healthcare businesses. He led the start up in 1986 of Invetech, an Australian contract research and development company that specializes in healthcare products and complex instruments for international markets. Invetech was merged with Australian Securities Exchange listed Vision Systems Limited in 1993, and Dr. Fox took over as Group Managing Director of the combined entity. In January 2007, Vision Systems Ltd by then a leading global cancer diagnostics company, was acquired by Danaher Corporation. Following the acquisition of Vision Systems, Dr Fox left the company to work in an advisory capacity on several boards globally. Prior to Invetech, Dr. Fox spent seven years working as a consultant and director with Cambridge (UK) based PA Technology. Dr. Fox currently serves as a director of TTP Group plc (UK) and as a director of Novasyte LLC. In the recent past Dr Fox was a director of Air New Zealand Ltd and Chairman of Biota Pharmaceuticals Inc.. Dr. Fox received his Bachelor's, Master's and Ph.D. degrees in engineering from the University of Melbourne.
Mr. Faulkner has served on the board of directors of GenMark Diagnostics, Inc. since March 2010. Mr. Faulkner was appointed to the board of directors of Osmetech plc in August 2008, serving as Non-Executive Chairman until December 2008. He is also currently a member of the board of directors of AspenBio Pharma, an emerging biotechnology company engaged in the research, development, manufacture, and commercialization of novel diagnostics. He also served as Executive Chair and Interim Chief Executive Officer of AspenBio Pharma from February 2009 until March 2010. Prior to Aspen, Mr. Faulkner was President and Chief Executive Officer and a director of Digene, a developer of gene-based diagnostic tests from December 2006 until consummation of Qiagen's acquisition of Digene. He continued until January 2009 as a consultant to Qiagen, a global provider of innovative sample and assay technologies and molecular diagnostic products and platforms. From 1998 until March 2006, Mr. Faulkner served in several executive roles at Invitrogen Corp., a life sciences company, including Senior Vice President, Strategic Business Units and SVP International. Mr. Faulkner's career also includes 15 years with Abbott Laboratories in various manufacturing and engineering management roles. Mr. Faulkner received a B.S. in Industrial Relations from the University of North Carolina, Chapel Hill and an M.A. in Business Management from Webster University.
Ms. Giles has served on the board of directors of GenMark Diagnostics, Inc. since March 2015. Ms. Giles has been the President and CEO of Giles & Associates Consultancy since 2000, and CEO of Optivara, Inc. since 2013. Giles & Associates is a privately held management consulting firm that specializes in global strategy development, market intelligence, and business development transactions. The firm advises corporate boards, CEOs, and executive leadership teams on strategic direction, portfolio optimization, and monitoring performance. From 1996-2000, Ms. Giles was Vice President of Strategy Development, at G.D. Searle & Company, where she oversaw global pharmaceutical strategic planning, portfolio decision analysis, portfolio optimization, and transaction analysis. She previously served as a member of the board of directors of Durata Therapeutics, Inc., from August 2012 until its acquisition by Actavis plc in November 2014. Ms. Giles received a B.S. from Juniata College and has completed Executive Management Programs at both Stanford and the University of Chicago.
Mr. Kagnoff has served on the board of directors of GenMark Diagnostics, Inc. since March 2015. Mr. Kagnoff has served as a partner at DLA Piper (US) since April 2008. Prior to joining DLA Piper, he was a stockholder at Heller Ehrman LLP. Mr. Kagnoff has been advising boards of directors of both public and private companies for over 20 years, with a focus on life sciences and technology companies. He has provided legal and business advice on a range of topics, including strategic transactions, corporate governance, and compensation matters. Mr. Kagnoff received a B.A. and B.S. degree from the University of Pennsylvania, and a J.D. from the University of California, Berkeley’s Boalt Hall School of Law.
Mr. Massarany has served as President and Chief Executive Officer and Director since May 2011. Mr. Massarany has over 25 years of healthcare, life sciences, and diagnostics experience and has held various global leadership positions with Ventana, Roche Diagnostics, Bayer Diagnostics, and Chiron Diagnostics. Mr. Massarany received a B.S. degree in Microbiology and Immunology from Monash University, Australia and an M.B.A. from Melbourne University, Australia.
Mr. O'Boyle served on the board of directors of GenMark Diagnostics, Inc. since March 2010. Mr. O'Boyle is also a member of the board of directors of the following publicly traded companies: Tornier N.V, Durata Therapeutics and Zeltiq. Previously, Mr. O'Boyle has served as Senior Vice President and Chief Financial Officer at Advanced BioHealing, Inc. focused on the diabetes market and NuVasive, Inc., which is focused on the design, development and marketing of products for the surgical treatment of spine disorders. Prior to that, Mr. O'Boyle served in various positions with ChromaVision Medical Systems, Inc., a diagnostics company specializing in the oncology market, including as its Chief Financial Officer and Chief Operating Officer. Also, Mr. O'Boyle held various positions with Albert Fisher North America, Inc., an international food company, before it was sold in 1996, including Chief Financial Officer and Senior Vice President of Operations. Mr. O'Boyle received a B.S. in Accounting from the Rochester Institute of Technology and successfully completed the Executive Management Program at the University of California at Los Angeles, John E. Anderson Graduate Business School.